Geneva, Switzerland and Boston, MA – October 31, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…
Tag: 2017
ObsEva SA Announces $60.0 Million Private Placement with Existing and New Investors
Geneva, Switzerland and Boston, MA – 10 October, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…
ObsEva at Rodman & Renshaw Annual Global Investment Conference
Company Management will be presenting and holding one-on-one meetings with investors at Rodman & Renshaw 19th Annual Global Investment Conference. Date &…
ObsEva SA Announces Presentation Related to its PGF2alpha Receptor Antagonist at ACCP 2017 Annual Meeting
Phase 1 clinical trial results in healthy subjects support cardiac safety of OBE022 Geneva, Switzerland and Boston, MA – 11 September, 2017 – ObsEva SA (NASDAQ: OBSV),…
ObsEva SA Announces the Completion of Patient Recruitment in the IMPLANT2 Phase 3 Clinical Trial in Assisted Reproductive Technology Ahead of Schedule
Geneva, Switzerland and Boston, MA – 06 September, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…
ObsEva at Baird Global Healthcare Conference
Company Management will be presenting and holding one-on-one meetings with investors at the Baird Global Healthcare Conference. Date & Time: 06 September…
ObsEva SA to Attend Baird Global Healthcare Conference and Rodman & Renshaw Annual Global Investment Conference in NYC
Geneva, Switzerland and Boston, MA – 30 August, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…
Q2 Report 2017
ObsEva at Wedbush PacGrow Healthcare Conference
Company Management will be presenting and holding one-on-one meetings at the Wedbush PacGrow Healthcare Conference. Date & Time: 16 August 2017 at…
ObsEva Reports Second Quarter 2017 Financial Results and Provides Business Update
– Patient Enrollment Progressing for late stage clinical programs in Assisted Reproductive Technology, Uterine Fibroids, and Endometriosis – Geneva, Switzerland and Boston,…